Duality Biologics Revenue

Biotechnology Research • Shanghai, China • 21-50 Employees

Duality Biologics revenue & valuation

Annual revenue	$4,106,640
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$13,200,000
Total funding	$90,000,000

Key Contacts at Duality Biologics

Cici Cao

Hr Director, Talent Acquisition China & U.S.

Swan Si

Executive Director Human Resources

诚诚王

Director, Clinical Supply & Cta

Ling Li

Senior Director

Jimin Zhang

Associate Director, Translational Medicine

Ivy Wang

Associate Director, Portfolio Strategy

Guodong Gordon

Director

Jiajun Mei

Director, Regulatory Affairs

Yu- Lin

Senior Medical Director

Melody Lee

Executive Assistant To Chief Executive Officer, Bd Manager

Company overview

Headquarters	Shanghai, China
Phone number	+862126018730
Website	dualitybiologics.com
NAICS	541714
Keywords	ADC
Founded	2020
Employees	21-50
Socials

Duality Biologics Email Formats

Duality Biologics uses 4 email formats. The most common is {first name}.{last name} (e.g., john.doe@dualitybiologics.com), used 69% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@dualitybiologics.com	69%
{first initial}.{last name}	j.doe@dualitybiologics.com	24.1%
{first initial}{last name}.{last name}	jdoe.doe@dualitybiologics.com	3.4%
{last name}	doe@dualitybiologics.com	3.4%

About Duality Biologics

About DualityBio DualityBio is a clinical-stage company focusing on the discovery and development of the next generation ADC therapeutics for patients with cancer and autoimmune diseases. DualityBio has successfully established a number of next generation Antibody-Drug Conjugate (ADC) technology platforms with global intellectual property rights. Building upon deep understanding of disease biology and translational capability, DualityBio has advanced 4 assets into global clinical studies, and developed more than 10 innovative product candidates which are currently in preclinical stage. Additionally, DualityBio is continuing evolving its novel protein engineering and ADC technology platforms for the next wave of “super ADC” molecules including diverse payload classes, bispecific ADCs and dual payload ADCs. For more information, please visit www.dualitybiologics.com. 关于映恩生物映恩生物（Duality Biologics）是一家临床阶段的创新生物药企，专注于为全球癌症患者和自身免疫性疾病患者研发新一代 ADC 疗法。映恩生物已成功构建了多个具有全球知识产权的新一代抗体偶联药物（ADC）技术平台。基于对疾病生物学机制的深入研究和探索，映恩生物已经拥有四项临床管线与十多项临床前创新项目并持续改进其新型蛋白工程和ADC技术平台，以开发下一代“超级ADC”分子，包括全新作用机制载荷、双特异性ADC和双有效载荷ADC。映恩生物已与海内外多个跨国药企达成多项重磅授权合作，并在全球开展多个国际多中心（MRCT）关键性临床研究。致力于成为世界领先的ADC公司。如需更多信息，请访问www.dualitybiologics.com

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Director

Entry

Senior

Employees by Department

Duality Biologics has 25 employees across 8 departments.

Departments

Number of employees

Funding Data

Explore Duality Biologics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2021-06-19	5	$90,000,000

Funding Insights

$90,000,000

Total funding amount

$90,000,000

Most recent funding amount

Number of funding rounds

Frequently asked questions

Duality Biologics is located in Shanghai, CN.

You can reach Duality Biologics at +862126018730.

Duality Biologics generates an estimated annual revenue of $4,106,640. This revenue figure reflects the company's market position and business performance in its industry.

Duality Biologics has an estimated valuation of $13,200,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Duality Biologics was founded in 2020, making it 6 years old. The company has established itself as a significant player in its industry over this time.

Duality Biologics has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

Duality Biologics has raised a total of $90,000,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.